| Literature DB >> 32455754 |
Florent Tintillier1, Céline Moriou2, Sylvain Petek1,3, Marilyne Fauchon3, Claire Hellio3, Denis Saulnier4, Merrick Ekins5, John N A Hooper5, Ali Al-Mourabit2, Cécile Debitus1,3.
Abstract
Four new brominated tyrosine metabolites,Entities:
Keywords: Pseudoceratina; Verongiida; antifouling; bromotyrosine; quorum sensing inhibitory activity; sponge
Mesh:
Substances:
Year: 2020 PMID: 32455754 PMCID: PMC7281015 DOI: 10.3390/md18050272
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of the isolated bromotyrosine metabolites.
1H NMR (500 MHz) and 13C NMR (125 MHz) data for aplyzanzines C (1) and D (2) in CD3OD and aplyzanzine A data (in CDCl3 + CD3OD (10:1)) from the literature.
| Position | Aplyzanzine C (1) | Aplyzanzine D (2) | Aplyzanzine A | |||
|---|---|---|---|---|---|---|
| No. | δC, Type | δH, Mult | δC, Type | δH, Mult | δC, Type | δH, Mult |
| 1 | 168.3, C | - | 167.2, C | - | 170.8, C | - |
| 2 | 66.3, CH | 4.65, m | 65.9, CH | 4.41, m | 69.8, CH | 3.14, dd (4.5, 8.8) |
| 3 | 35.1, CH2 | 2.97–3.47, m | 30.4, CH2 | 2.93–3.30, m | 31.6, CH2 | 2.71, dd (4.5, 13.8) |
| 4 | 134.0, C | - | 132.0, C | - | 137.6, C | - |
| 5, 9 | 135.6, CH | 7.55, s | 133.6, CH | 7.36, s | 133.2, CH | 7.31, s |
| 6, 8 | 119.4, C | - | 110.5, C | - | 117.6, C | - |
| 7 | 155.7, C | - | 149.2, C | - | 152.3, C | - |
| 10, 11 | 42.7, CH3 | 2.91, s | 42.1, CH3 | 2.71, br s | 41.51, CH3 | 2.26, s |
| 12 | 61.4, CH3 | 3.84, s | 61.4, CH3 | 3.74, s | ||
| 1’ | 50.5, CH2 | 3.47, m | 50.4, CH2 | 3.54, m | 39.8, CH2 | 3.28, dt (2.8, 7.2) |
| 2’ | 32.8, CH2 | 2.57, m | 32.4, CH2 | 2.53, m | 34.2, CH2 | 2.54, m |
| 3’ | 139.5, C | - | 133.9, C | - | 137.9, C | - |
| 4’, 8’ | 134.5, CH | 7.51, s | 135.1, CH | 7.54, s | 132.8, CH | 7.23, s |
| 5’, 7’ | 119.1, C | - | 117.3, C | - | 117.7, C | - |
| 6’ | 152.7, C | - | 153.4, C | - | 150.9, C | - |
| 9’ | 35.8, CH3 | 2.65, s | 35.4, CH3 | 2.64, s | ||
| 10’ | 61.0, CH3 | 3.83, s | ||||
| 1” | 71.8, CH2 | 4.11, m | 69.7, CH2 | 3.96, t (5.5) | ||
| 2” | 29.2, CH2 | 2.21, m | 25.4, CH2 | 2.18, m | ||
| 3” | 39.0, CH2 | 3.27, m | 55.4, CH2 | 3.16, m | ||
| 4”, 5” | 42.92, CH3 | 2.67, s | ||||
Figure 2Structure of aplyzanzine A.
Figure 3COSY and key HMBC correlations for aplyzanzines C (1) and D (2).
1H NMR (500 MHz) and 13C NMR (125 MHz) data for aplyzanzines E (3) and F (4) in CD3OD.
| Position | Aplyzanzine E (3) | Aplyzanzine F (4) | ||
|---|---|---|---|---|
| No. | δC, Type | δH, Mult | δC, Type 1 | δH, Mult |
| 1 | 168.9, C | - | - | |
| 2 | 120.7, CH | 6.60, d (15) | ||
| 3 | 138.4, CH | 6.96, d (15) | ||
| 4 | 133.3, C | - | 135.6, C | - |
| 5, 9 | 132.9, CH | 7.69, s | ||
| 6, 8 | 119.9, C | - | 119.7, C | - |
| 7 | 156.5, C | - | 156.2, C | - |
| 10 | 61.1, CH3 | 3.88, s | 61.3, CH3 | 3.87, s |
| 1’ | 52.2, CH2 | 3.85, m | ||
| 2’ | 34.2, CH2 | 2.86, m | ||
| 3’ | 135.2, C | - | 133.1, C | - |
| 4’, 8’ | 134.9, CH | 7.40, s | ||
| 5’, 7’ | 119.2, C | - | 112.5, C | - |
| 6’ | 152.7, C | - | 151.9, C | - |
| 9’ | 34.2, CH3 | 3.09, s | ||
| 1” | 71.5, CH2 | 4.10, m | ||
| 2” | 29.1, CH2 | 2.19, m | ||
| 3” | 38.6, CH2 | 3.30, m | ||
1 Presence of two rotamers in a 70/30 ratio. In bold, the data of the predominant form.
Figure 4COSY and key HMBC correlations for aplyzanzines E (3) and F (4).
Luminescence curves of wild strain BB120 and its three derived double mutants (JAF 375, JMH 597, and JMH 612) in the presence of purified compounds tested at two concentrations or not (control).
| ____: Control without Product; - - -: 50 µg/mL; ……: 5 µg/mL | ||||
|---|---|---|---|---|
| No. | BB120 | JAF 375 (CAI-1 +) | JMH 597 (AI-2 +) | JMH 612 (HAI-1 +) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| nt 1 | nt | nt |
|
|
| nt | nt | nt |
1 nt = not tested; Y-axis: relative luminescence units (RLU); X-axis: n cycles of 10 min.
Activities of the purified compounds 1–6 compared to Seanine 211, bromotyrosine derivatives taken from the literature against microorganisms involved in biofouling (MIC in µM).
| Microalgae | Marine Bacteria | |||||
|---|---|---|---|---|---|---|
| Mol. |
|
|
|
|
|
|
|
| ||||||
|
|
|
|
| - | - | - |
|
| - 2 | - | - | - | 1.48 | - |
|
| - | - | - |
|
| - |
|
| - | - |
| - | - | - |
|
| - | - | - |
|
|
|
|
| - | - | - | - | - | - |
| Seanine 3 |
|
|
|
| 3.5 | 3.5 |
| Syn. A 4 | - | 20 | 20 | - | - | 20 |
| Syn. C 5 |
| 2 | 2 | 2 | 2 | 20 |
| Pul. A 6 | - | - | 30 | - |
| - |
| Pul. B 7 | - | - | - | - | 20 | - |
| Ianthel. 8 | - | - | - | - |
| - |
|
| ||||||
|
|
|
|
| 1.37 | - | - |
|
| 1.48 | 1.48 | - | - | - | 1 |
|
| - | - | - | - |
| - |
|
| - | - | - | - | - | - |
|
| 19 | 1.9 |
| - | - | - |
|
| - | - | - | - |
| - |
| Seanine |
|
|
|
|
| 3.5 |
| Syn. A | 20 | 20 | 20 |
|
| - |
| Syn. C |
|
| 2 |
|
| 2 |
| Pul. A |
| - | - | - | - |
|
| Pul. B | - | - | - | - | - | - |
| Ianthel. | - | - | - | 21 |
| 2.1 |
1 Numbers in bold represent the best biological activities; 2 compound inactive at ≥ 10 μg/mL concentrations; 3 Seanine 211; 4 synoxazolidinone A; 5 synoxazolidinone C; 6 pulmonarin A; 7 pulmonarin B; 8 ianthelline.